vs
Side-by-side financial comparison of QUALYS, INC. (QLYS) and Twist Bioscience Corp (TWST). Click either name above to swap in a different company.
QUALYS, INC. is the larger business by last-quarter revenue ($175.3M vs $103.7M, roughly 1.7× Twist Bioscience Corp). QUALYS, INC. runs the higher net margin — 30.3% vs -29.4%, a 59.7% gap on every dollar of revenue. On growth, Twist Bioscience Corp posted the faster year-over-year revenue change (16.9% vs 10.1%). QUALYS, INC. produced more free cash flow last quarter ($74.9M vs $-34.8M).
Qualys, Inc. is an American technology firm based in Foster City, California, specializing in cloud security, compliance and related services.
Twist Bioscience is a public biotechnology company based in South San Francisco that manufactures synthetic DNA and DNA products for customers in a wide range of industries. Twist was founded in 2013 by Emily Leproust, Bill Banyai, and Bill Peck.
QLYS vs TWST — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $175.3M | $103.7M |
| Net Profit | $53.1M | $-30.5M |
| Gross Margin | 83.4% | 52.0% |
| Operating Margin | 33.6% | -31.7% |
| Net Margin | 30.3% | -29.4% |
| Revenue YoY | 10.1% | 16.9% |
| Net Profit YoY | 20.9% | 3.4% |
| EPS (diluted) | $1.47 | $-0.50 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $175.3M | $103.7M | ||
| Q3 25 | $169.9M | — | ||
| Q2 25 | $164.1M | — | ||
| Q1 25 | $159.9M | — | ||
| Q4 24 | $159.2M | — | ||
| Q3 24 | $153.9M | — | ||
| Q2 24 | $148.7M | — | ||
| Q1 24 | $145.8M | — |
| Q4 25 | $53.1M | $-30.5M | ||
| Q3 25 | $50.3M | — | ||
| Q2 25 | $47.3M | — | ||
| Q1 25 | $47.5M | — | ||
| Q4 24 | $44.0M | — | ||
| Q3 24 | $46.2M | — | ||
| Q2 24 | $43.8M | — | ||
| Q1 24 | $39.7M | — |
| Q4 25 | 83.4% | 52.0% | ||
| Q3 25 | 83.6% | — | ||
| Q2 25 | 82.4% | — | ||
| Q1 25 | 81.9% | — | ||
| Q4 24 | 81.8% | — | ||
| Q3 24 | 81.3% | — | ||
| Q2 24 | 82.2% | — | ||
| Q1 24 | 81.3% | — |
| Q4 25 | 33.6% | -31.7% | ||
| Q3 25 | 35.3% | — | ||
| Q2 25 | 31.3% | — | ||
| Q1 25 | 32.4% | — | ||
| Q4 24 | 31.0% | — | ||
| Q3 24 | 29.2% | — | ||
| Q2 24 | 32.3% | — | ||
| Q1 24 | 30.7% | — |
| Q4 25 | 30.3% | -29.4% | ||
| Q3 25 | 29.6% | — | ||
| Q2 25 | 28.8% | — | ||
| Q1 25 | 29.7% | — | ||
| Q4 24 | 27.6% | — | ||
| Q3 24 | 30.0% | — | ||
| Q2 24 | 29.4% | — | ||
| Q1 24 | 27.2% | — |
| Q4 25 | $1.47 | $-0.50 | ||
| Q3 25 | $1.39 | — | ||
| Q2 25 | $1.29 | — | ||
| Q1 25 | $1.29 | — | ||
| Q4 24 | $1.19 | — | ||
| Q3 24 | $1.24 | — | ||
| Q2 24 | $1.17 | — | ||
| Q1 24 | $1.05 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $250.3M | $197.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $561.2M | $456.1M |
| Total Assets | $1.1B | $638.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $250.3M | $197.9M | ||
| Q3 25 | $225.3M | — | ||
| Q2 25 | $194.0M | — | ||
| Q1 25 | $290.7M | — | ||
| Q4 24 | $232.2M | — | ||
| Q3 24 | $235.4M | — | ||
| Q2 24 | $281.2M | — | ||
| Q1 24 | $273.8M | — |
| Q4 25 | $561.2M | $456.1M | ||
| Q3 25 | $529.4M | — | ||
| Q2 25 | $508.2M | — | ||
| Q1 25 | $498.0M | — | ||
| Q4 24 | $477.1M | — | ||
| Q3 24 | $449.6M | — | ||
| Q2 24 | $427.8M | — | ||
| Q1 24 | $404.2M | — |
| Q4 25 | $1.1B | $638.1M | ||
| Q3 25 | $1.0B | — | ||
| Q2 25 | $999.5M | — | ||
| Q1 25 | $996.5M | — | ||
| Q4 24 | $973.5M | — | ||
| Q3 24 | $908.3M | — | ||
| Q2 24 | $876.6M | — | ||
| Q1 24 | $861.8M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $75.7M | $-24.8M |
| Free Cash FlowOCF − Capex | $74.9M | $-34.8M |
| FCF MarginFCF / Revenue | 42.8% | -33.5% |
| Capex IntensityCapex / Revenue | 0.4% | 9.6% |
| Cash ConversionOCF / Net Profit | 1.42× | — |
| TTM Free Cash FlowTrailing 4 quarters | $304.4M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $75.7M | $-24.8M | ||
| Q3 25 | $90.4M | — | ||
| Q2 25 | $33.8M | — | ||
| Q1 25 | $109.6M | — | ||
| Q4 24 | $47.7M | — | ||
| Q3 24 | $61.0M | — | ||
| Q2 24 | $49.8M | — | ||
| Q1 24 | $85.5M | — |
| Q4 25 | $74.9M | $-34.8M | ||
| Q3 25 | $89.5M | — | ||
| Q2 25 | $32.4M | — | ||
| Q1 25 | $107.5M | — | ||
| Q4 24 | $41.9M | — | ||
| Q3 24 | $57.6M | — | ||
| Q2 24 | $48.8M | — | ||
| Q1 24 | $83.5M | — |
| Q4 25 | 42.8% | -33.5% | ||
| Q3 25 | 52.7% | — | ||
| Q2 25 | 19.8% | — | ||
| Q1 25 | 67.3% | — | ||
| Q4 24 | 26.3% | — | ||
| Q3 24 | 37.4% | — | ||
| Q2 24 | 32.8% | — | ||
| Q1 24 | 57.2% | — |
| Q4 25 | 0.4% | 9.6% | ||
| Q3 25 | 0.5% | — | ||
| Q2 25 | 0.8% | — | ||
| Q1 25 | 1.3% | — | ||
| Q4 24 | 3.7% | — | ||
| Q3 24 | 2.2% | — | ||
| Q2 24 | 0.7% | — | ||
| Q1 24 | 1.4% | — |
| Q4 25 | 1.42× | — | ||
| Q3 25 | 1.80× | — | ||
| Q2 25 | 0.71× | — | ||
| Q1 25 | 2.31× | — | ||
| Q4 24 | 1.09× | — | ||
| Q3 24 | 1.32× | — | ||
| Q2 24 | 1.14× | — | ||
| Q1 24 | 2.15× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
QLYS
| Sales Channel Through Intermediary | $88.6M | 51% |
| Sales Channel Directly To Consumer | $86.7M | 49% |
TWST
| Industrial Chemicals | $37.2M | 36% |
| Diagnostics | $35.3M | 34% |
| Food Or Agriculture | $12.8M | 12% |
| Academic Research | $12.2M | 12% |
| Health Care | $6.1M | 6% |
